Citations

Clear

6273 citation(s) found for "To, Andrew".

Obstructive Sleep Apnea, Inflammation, and the Metabolic Syndrome
Calvin, Andrew D. , Albuquerque, Felipe N. , López-Jiménez, Francisco , Somers, Virend K. , Calvin, Andrew D

Mayo Clinic

Metabolic Syndrome and Related Disorders | April 3, 2009 | Volume: 7 | Issue: 4 | Pages: 271-277

10.1089/met.2008.0093 | PMID 19344228 Get It

The combination of metabolic syndrome and obstructive sleep apnea (OSA) has been termed “syndrome Z.” The prevalence of both OSA and metabolic syndrome is increasing worldwide, in part linked to the epidemic of obesity. Beyond their epidemiologic relationship, growing evidence suggests that OSA may be causally related to metabolic syndrome. We are only beginning to understand the potential mechanisms underlying the OSA–metabolic syndrome interaction. Although there is no clear consensus, there is growing evidence that alterations in the hypothalamic–pituitary axis, generation of reactive oxygen species (ROS) due to repetitive hypoxia, inflammation, and generation of adipokines may be implicated in the changes associated with both OSA and metabolic syndrome. Whether some or all of these metabolic alterations mechanistically link OSA to metabolic syndrome remains to be proven, but it is an area of intense scientific interest.
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation
Dillon, Stacey R. , Ziesmer, Steven C., Feldman, Andrew L. , Ansell, Stephen M. , Cerhan, James R. , Novak, Anne J. , Gupta, Mamta , Witzig, Thomas E. , Feldman, Andrew L , Cerhan, James R

Mayo Clinic

Blood | March 26, 2009 | Volume: 113 | Issue: 21 | Pages: 5206-5216

10.1182/blood-2008-09-179762 | PMID 19321861 Get It

Abstract A proliferation-inducing ligand (APRIL), as well as its receptors transmembrane activator and calcium-modulating cyclophilin ligand (CAML) interactor (TACI) and B-cell maturation antigen (BCMA), has been shown to be important in B-cell biology, and overexpression of APRIL in mice results in development of lymphoma. Limited data are available on APRIL-specific signaling responses, but knockout models suggest that signaling through TACI is critical to B-cell homeostasis. To better understand the mechanism by which APRIL exerts its effects and how it may contribute to lymphomagenesis, we sought to characterize the outcome of APRIL-TACI interactions. In support of murine studies, we find that APRIL induces proliferation of human patient follicular lymphoma (FL) B cells in a TACI-dependent manner. This study also shows that APRIL is expressed within the tumor microenvironment and that, upon engagement with TACI, APRIL mediates activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Activation of PI3K via APRIL results in phosphorylation of Akt and mammalian target of rapamycin (mTOR) and the mTOR-specific substrates p70S6 kinase and 4E-binding protein 1 in a TACI-dependent manner. APRIL-mediated signaling also results in phosphorylation of Rb and up-regulation of cyclin D1. These studies are the first to characterize APRIL-TACI–specific signaling and suggest a role for this ligand-receptor pair in FL B-cell growth.
Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo
Xu, Zhili , Hofherr, Sean, Barry, Michael A. , Byrnes, Andrew P. , Tian, Jie , Smith, Jeffrey S. , Barry, Michael A

Mayo Clinic

Journal of Virology | March 26, 2009 | Volume: 83 | Issue: 11 | Pages: 5648-5658

10.1128/jvi.00082-09 | PMID 19321608 Get It

ABSTRACTUnderstanding innate immunity is key to improving the safety of adenovirus (Ad) vectors for systemic gene therapy. Ad has been shown to activate complement in vitro, but activation of complement after Ad injection in vivo has not been directly measured. Using complement protein C3a as a marker of complement activation, we show that types 2 and 5 human Ads cause rapid complement activation after intravenous injection in mice. Unexpectedly, the mechanisms in vivo were different than those in vitro. Antibodies were critical for the activation of complement by Ad in vitro, but antibodies were not required in vivo. The classical pathway was required in vitro, whereas complement activation in vivo involved both classical and nonclassical pathways as well as the reticuloendothelial system. Remarkably, the entry-deficient Ad mutantts1 was completely unable to activate complement in vivo even though it was fully able to activate complement in vitro. This result demonstrates that the complement system senses intravenously injected Ad primarily by detecting the effects of Ad on cells rather than through direct interaction of complement with virions. Encouragingly, shielding Ad with polyethylene glycol was effective at reducing complement activation both in vitro and in vivo. In summary, intravenously injected Ad rapidly activates complement through multiple pathways, but these pathways are different than those identified by in vitro studies. In vitro studies are poorly predictive of in vivo mechanisms because Ad virions activate complement through indirect mechanisms in vivo.
Molecular evolution of the junctophilin gene family
Garbino, Alejandro , Oort, Ralph J. van, Dixit, Sayali S., Landstrom, Andrew P. , Ackerman, Michael J. , Wehrens, Xander H.T. , Landstrom, Andrew P , Wehrens, Xander H T

Mayo Clinic

Physiological Genomics | March 25, 2009 | Volume: 37 | Issue: 3 | Pages: 175-186

10.1152/physiolgenomics.00017.2009 | PMID 19318539 Get It

Junctophilins (JPHs) are members of a junctional membrane complex protein family important for the physical approximation of plasmalemmal and sarcoplasmic/endoplasmic reticulum membranes. As such, JPHs facilitate signal transduction in excitable cells between plasmalemmal voltage-gated calcium channels and intracellular calcium release channels. To determine the molecular evolution of the JPH gene family, we performed a phylogenetic analysis of over 60 JPH genes from over 40 species and compared conservation across species and different isoforms. We found that JPHs are evolutionary highly conserved, in particular the membrane occupation and recognition nexus motifs found in all species. Our data suggest that an ancestral form of JPH arose at the latest in a common metazoan ancestor and that in vertebrates four isoforms arose, probably following two rounds of whole genome duplications. By combining multiple prediction techniques with sequence alignments, we also postulate the presence of new important functional regions and candidate sites for posttranslational modifications. The increasing number of available sequences yields significant insight into the molecular evolution of JPHs. Our analysis is consistent with the emerging concept that JPHs serve dual important functions in excitable cells: structural assembly of junctional membrane complexes and regulation of intracellular calcium signaling pathways.
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study
Song, Honglin , Ramus, Susan J. , Kjær, Susanne K. , DiCioccio, Richard A., Chenevix‐Trench, Georgia , Pearce, Celeste Leigh, Høgdall, Estrid , Whittemore, Alice S. , McGuire, Valerie , Høgdall, Claus , Blaakær, Jan , Wu, Anna H. , Berg, David J. Van Den, Menon, Usha , Jacobs, Ian , Webb, Penny M., Beesley, Jonathan, Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Rossing, Mary Anne, Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Goodman, Marc T. , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Ness, Roberta B., Moysich, Kirsten B., Goode, Ellen L. , Vierkant, Robert A. , Cunningham, Julie M. , Anderson, S. Keith , Schildkraut, Joellen M. , Iversen, Edwin S., Moorman, Patricia G. , García‐Closas, Montserrat , Lissowska, Jolanta , Brinton, Louise A. , Ponder, Bruce A.J., Easton, Douglas F. , Gayther, Simon A. , Pharoah, Paul D.P., Webb, Penelope M. , Bowtell, David D.L. , Stram, Daniel O. , Gentry‐Maharaj, Aleksandra , Webb, Penny M., Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Doherty, Jennifer A. , Berchuck, Andrew , Chanock, Stephen Jacob , Anton‐Culver, Hoda , Ziogas, Argyrios , Brewster, Wendy R. , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Human Molecular Genetics | March 20, 2009 | Volume: 18 | Issue: 12 | Pages: 2297-2304

10.1093/hmg/ddp138 | PMID 19304784 Get It

Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke
Zoppo, Gregory J. del, Levy, David E., Wasiewski, Warren W., Pancioli, Arthur , Demchuk, Andrew M., Trammel, James, Kaste, Markku , Albers, Gregory W. , Ringelstein, Eric B., Demaerschalk, Bart M.

Mayo Clinic

Stroke | March 19, 2009 | Volume: 40 | Issue: 5 | Pages: 1687-1691

10.1161/strokeaha.108.527804 | PMID 19299642 Get It

Background and Purpose— Epidemiological studies have found strong correlations between elevated plasma fibrinogen levels and both ischemic stroke incidence and stroke mortality. Little is known about the influence of fibrinogen levels on functional stroke outcome. Methods— Placebo data from the Stroke Treatment with Ancrod Trial (STAT) and European Stroke Treatment with Ancrod Trial (ESTAT) were analyzed. Fibrinogen levels were determined within 3 hours (STAT) or 6 hours (ESTAT) of stroke onset and at preset intervals throughout 5 days of intravenous infusions. Barthel Index scores at 90 days quantified functional outcomes. The association between initial fibrinogen levels and functional outcomes was evaluated using a multiple logistic regression analysis. Results— Fibrinogen levels increased gradually over the first 24 hours from a pretreatment median value of 340 mg/dL to a 24-hour median value of 376 mg/dL. In a univariate analysis, the proportion of patients with good functional outcome decreased with increasing quartiles of initial fibrinogen levels in both STAT (36.0% to 26.2%) and ESTAT (53.8% to 24.8%). In a multifactorial analysis, the same trend was observed. Patients with initial fibrinogen levels <450 mg/dL had better outcomes in both studies; the difference (42.0% versus 21.6%) was significant in ESTAT ( P =0.0006), even when corrected for age and initial stroke severity. Conclusion— The independent association of higher initial fibrinogen levels with poor outcome needs to be verified using a larger acute stroke dataset. Even in the present small populations, the apparent association of these 2 variables suggests that treatments designed to reduce fibrinogen levels could potentially be important in treating acute ischemic stroke.
The Pneumocystis Meiotic PCRan1p Kinase Exhibits Unique Temperature-Regulated Activity
Burgess, Joshua W., Villegas, Leah R., Lamont, Jeffrey D., Baden, Elizabeth M., Ramı́rez-Alvarado, Marina , Kottom, Theodore J. , Limper, Andrew H. , Ramirez-Alvarado, Marina

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 13, 2009 | Volume: 41 | Issue: 6 | Pages: 714-721

10.1165/rcmb.2008-0098oc | PMID 19286979 Get It

Abstract Pneumocystis organisms are opportunistic fungal pathogens that cause significant pneumonia in immune-compromised hosts. Recent evidence has suggested that Pneumocystis carinii exists as separate mating types, and expresses and regulates proteins that govern meiosis and progression of the life cycle. This study was undertaken to investigate the activity of three life cycle–regulatory proteins in Pneumocystis, including two proteins essential in mating signaling, and a putative meiotic regulator, to determine the conditions under which they are most active. This study used V5/HIS-tagged PCRan1p, PCSte20p, and PCCbk1, purified from Saccharomyces cerevisiae strain, INVSC, as well as an in vitro Escherichia coli protein expression system to determine the optimal expression conditions of each protein in the presence of varying pH, temperature, and metal ions. These studies demonstrate an atypical enzymatic activity in PCRan1p, whereby the kinase was most active in the environmental conditions between 10 and 25°C, compared with a dramatic reduction in activity above 30°C, temperatures typically found within mammalian hosts. Circular dichroism and fluorescence spectroscopy suggest that PCRan1p becomes partially unfolded at 25°C, leading to its most active conformation, whereas continued unfolding as temperature increases results in strongly suppressed activity. These studies suggest that, in vivo, while under conditions within the mammalian lung (typically 37°C), PCRan1p kinase activity is largely suppressed, allowing better conditions for the activation of meiosis, whereas in ex vivo environments, PCRan1p kinase activity increases to arrest progression of the life cycle until conditions become more favorable.
Hockey Education Program (HEP): A Statewide Measure of Fair Play, Skill Development, and Coaching Excellence
Smith, Aynsley M., Jorgenson, M. B., Sorenson, Matthew C., Margenau, David, Link, Andrew A., MacMillan, Michael, Stuart, Michael J.

Mayo Clinic

Journal of ASTM International | March 12, 2009 | Volume: 6 | Issue: 4 | Pages: 1-14

10.1520/jai101857 Get It

Abstract Following the death of a youth hockey coach in a fight with a parent in 2000, the Mayo Clinic Sports Medicine Center and Minnesota Hockey collaborated to implement a three-component Hockey Education Program (HEP). HEP was initiated in 2003 to ensure youth players develop sportsmanship, skills, and a Fair Play approach to the game. Another goal was to decrease attrition of players, coaches, and officials. Coaching Excellence, a component of HEP, is based on 25 years of youth sport research. The HEP manuals Coaches Who Never Lose and Sports and Your Child contain the philosophy, objectives, and guidelines to ensure implementation of HEP components across players, coaches, and parents. The Skill Development component emphasizes learning age-appropriate hockey skills though skill progression. Increasing the practice-to-game ratio to 3–4 practices per game greatly increases the maximum time players skate with the puck during developmental years. Pre- and post-season Skills Challenges allow coaches, players, and parents to gauge improvement, and structure practices to address identified skill deficits. The Fair Play (FP) component emphasizes sportsmanship. Teams earn a FP point each game if they incur less than a preset number of penalty minutes. A coach receiving a game misconduct or a parent/spectator asked to leave the game will cause the team to forfeit their FP point. FP points are factored into league standings across the state. This past season, 17 678 records of game data were obtained and 25 % (4420) were randomly selected for analysis. The data analysis permits comparison across seasons and changes are made accordingly. Based on four years of data, most Minnesota youth hockey games are played in a sportsmanlike manner. Checking from behind and head contact penalties have decreased since the penalty minutes for these dangerous infractions were increased.
Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer
Schildkraut, Joellen M. , Goode, Ellen L. , Clyde, Merlise A. , Iversen, Edwin S., Moorman, Patricia G. , Marks, Jeffrey R. , Lissowska, Jolanta , Brinton, Louise A. , Pepłońska, Beata , Cunningham, Julie M. , Vierkant, Robert A. , Rider, David N., Chenevix‐Trench, Georgia , Webb, Penelope M. , Beesley, Jonathan, Chen, Xiaoqing, Phelan, Catherine, Sutphen, Rebecca , Sellers, Thomas A. , Pearce, Leigh, Wu, Anna H. , Conti, David V. , Elund, Christopher K., Anderson, Rebecca L. , Goodman, Marc T. , Lurie, Galina, Carney, Michael E., Thompson, Pamela J., Gayther, Simon A. , Ramus, Susan J. , Jacobs, Ian , Kjær, Susanne K. , Høgdall, Estrid , Blaakær, Jan , Høgdall, Claus , Easton, Douglas F. , Song, Honglin , Whittemore, Alice S. , McGuire, Valerie , Quaye, Lydia, Terry, Kathryn L. , Hankinson, Susan E. , Tworoger, Shelley S. , García‐Closas, Montserrat , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Berchuck, Andrew , Chen, Xiaoqing, Berg, David Van Den , Pharoah, Paul D.P. , Anton‐Culver, Hoda , Ziogas, Argyrios , Cramer, Daniel W. , Calingaert, Brian , Chanock, Stephen Jacob , Sherman, Mark E. , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Webb, Penelope M , Vierkant, Robert A , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Conti, David V , Goodman, Marc T

Mayo Clinic

Cancer Research | March 10, 2009 | Volume: 69 | Issue: 6 | Pages: 2349-2357

10.1158/0008-5472.can-08-2902 | PMID 19276375 Get It

Abstract The p53 protein is critical for multiple cellular functions including cell growth and DNA repair. We assessed whether polymorphisms in the region encoding TP53 were associated with risk of invasive ovarian cancer. The study population includes a total of 5,206 invasive ovarian cancer cases (2,829 of which were serous) and 8,790 controls from 13 case-control or nested case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Three of the studies performed independent discovery investigations involving genotyping of up to 23 single nucleotide polymorphisms (SNP) in the TP53 region. Significant findings from this discovery phase were followed up for replication in the other OCAC studies. Mixed effects logistic regression was used to generate posterior median per allele odds ratios (OR), 95% probability intervals (PI), and Bayes factors (BF) for genotype associations. Five SNPs showed significant associations with risk in one or more of the discovery investigations and were followed up by OCAC. Mixed effects analysis confirmed associations with serous invasive cancers for two correlated (r2 = 0.62) SNPs: rs2287498 (median per allele OR, 1.30; 95% PI, 1.07–1.57) and rs12951053 (median per allele OR, 1.19; 95% PI, 1.01–1.38). Analyses of other histologic subtypes suggested similar associations with endometrioid but not with mucinous or clear cell cancers. This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region. [Cancer Res 2009;69(6):2349–57]
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Carson, Kenneth R. , Evens, Andrew M. , Richey, Elizabeth, Focosi, Daniele , Seymour, John F. , Laubach, Jacob P. , Bawn, Susie D., Gordon, Leo I. , Furman, Richard R. , Zelenetz, Andrew D. , Mamtani, Ronac , Raisch, Dennis W., Dorshimer, Gary W., Rosen, Steven T. , Muro, Kenji , Gottardi-Littell, Numa R., Talley, Robert L., Green, David , Major, Eugene O. , Bennett, Charles L. , Habermann, Thomas M. , Winter, Jane N. , Vose, Julie M. , Sartor, Oliver , Gordon, Leo I , Zelenetz, Andrew D , Evens, Andrew M , Focosi, Daniele

Mayo Clinic

Blood | March 6, 2009 | Volume: 113 | Issue: 20 | Pages: 4834-4840

10.1182/blood-2008-10-186999 | PMID 19264918 Get It

Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.